2026-05-17T01:18:29Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/101512025-06-23T17:44:05Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19608col_20.500.12105_19609

00925njm 22002777a 4500 dc Valenciano, Marta author Kissling, Esther author Reuss, Annicka author Rizzo, Caterina author Gherasim, Alin Manuel author Horváth, Judit Krisztina author Domegan, Lisa author Pitigoi, Daniela author Machado, Ausenda author Paradowska-Stankiewicz, Iwona Anna author Bella, Antonino author Larrauri, Amparo author Ferenczi, Annamária author Lazar, Mihaela author Pechirra, Pedro author Korczyńska, Monika Roberta author Pozo Sanchez, Francisco author Moren, Alain author 2016 Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2014/15. We undertook a multicentre case-control study in eight European countries to measure 2014/15 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed all or a systematic sample of ILI patients. We compared the odds of vaccination of ILI influenza positive patients to negative patients. We calculated adjusted VE by influenza type/subtype, and age group. Among 6,579 ILI patients included, 1,828 were A(H3N2), 539 A(H1N1)pdm09 and 1,038 B. VE against A(H3N2) was 14.4% (95% confidence interval (CI): -6.3 to 31.0) overall, 20.7% (95%CI: -22.3 to 48.5), 10.9% (95%CI -30.8 to 39.3) and 15.8% (95% CI: -20.2 to 41.0) among those aged 0-14, 15-59 and  ≥60  years, respectively. VE against A(H1N1)pdm09 was 54.2% (95%CI: 31.2 to 69.6) overall, 73.1% (95%CI: 39.6 to 88.1), 59.7% (95%CI: 10.9 to 81.8), and 22.4% (95%CI: -44.4 to 58.4) among those aged 0-14, 15-59 and  ≥60 years respectively. VE against B was 48.0% (95%CI: 28.9 to 61.9) overall, 62.1% (95%CI: 14.9 to 83.1), 41.4% (95%CI: 6.2 to 63.4) and 50.4% (95%CI: 14.6 to 71.2) among those aged 0-14, 15-59 and ≥60 years respectively. VE against A(H1N1)pdm09 and B was moderate. The low VE against A(H3N2) is consistent with the reported mismatch between circulating and vaccine strains. Euro Surveill. 2016;21(7):pii=30139. 10.2807/1560-7917.ES.2016.21.7.30139 1560-7917 1025-496X Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 26924024 http://hdl.handle.net/20.500.12105/10151 Influenza Influenza vaccine effectiveness Multicentre case-control study Vaccines and immunisation Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15